Atrial fibrillation : a common arrhythmia with possible dire consequences by Xuereb, Robert G.
Cardiology 
Atrial fibrillation: a common arrhythmia with 
possible dire consequences 
by Robert G Xuereb 
The diagnosis of atrial fibrillation (AF) is dinched on 
the electrocardiogram with the finding of fine baseline 
oscillations, absent P waves and irregular ventricular 
rhythm.1 It is the most common type of arrhythmia 
requiring medical care, with a prevalence of 1-2%.2 More 
than half of AF episodes are detected by continuous 
ambulatory ECG monitoring. Although uncommon in the 
younger age groups, less than 0.5% in 40-50 year olds, it 
affects 5-15% of the population by the age of 80 years. 
Classification of atrial fibrillation 
• First diagnosed AF is AF presenting for the first time. 
• Paroxysmal AF is recurrent and self-terminating AF. 
• Persistent AF lasts more than 7 days or is terminated by 
either electrical or pharmacological cardioversion. 
• Permanent AF is longstanding AF. 
Predisposing factors 
Hypertension is found in approximately 2/3 of all patients 
with AF.3 Uncontrolled blood pressure predisposes to 
AF. Heart failure is found in 30% of AF patients.3 It can 
be a consequence of or a cause of AF. Other causes of 
AF include valvular heart disease especially mitral valve 
disease, cardiomyopathies, atrial septal defects, coronary 
artery disease, thyrotoxicosis, obesity, metabolic syndrome, 
and sleep apnoea. Diabetes mellitus is found in 20% of 
patients with AF, chronic obstructive pulmonary disease is 
found in 10% of patients with AF, and chronic renal disease 
is found in 10-15% of patients with AF. 
Dire consequences of atrial fibrillation 
Death rate is doubled in patients with AF.4 Not only are 
approximately 20% of strokes due to AF, but these strokes 
are more severe than strokes of other origins.5 AF also 
often results in left ventricular dysfunction and in reduced 
quality of life and exercise capacity.6 
Pharmacological therapy for atrial fibrillation 
The principles of pharmacological therapy for AF are: 
(i) antithrombotic therapy, (iij treatment of underlying 
condition, Oiij termination of AF, Ov) maintenance of sinus 
rhythm, and (v) control of ventricular rate during AF. 
Antithrombotic therapy 
Mtithrombotic therapy is based on the risk category 
of stroke or systemic embolism. Oral anticoagulation 
therapy with a vitamin K antagonist aiming for an INR of 
2-3 is recommended in those patients with one 'definitive' 
risk factor - previous stroke, transient ischaemic attack, 
systemic embolus, the elderly (aged> 75) or valvular 
disease (mitral stenosis or prosthetic heart valves). It 
is also recommended in those patients with 2 or more 
'combination' risk factors - heart failure, hypertension, 
diabetes mellitus, female gender, age 65-74 years, and 
vascular disease. If 1 'combination' risk factor is present, 
either oral anticoagulation therapy or aspirin may be opted 
for. If no risk factors are present, aspirin 75-325mg daily is 
recommmded. 
Antiarrhythmic therapy 
The choice of the antiarrhythmic drug for cardioversion 
as well as for long-term management of AF depends 
on the underlying heart disease.1 Class IC agents 
propafenone and flecainide and the class III agent sotaIol 
are recommended in patients with moderate structural 
heart disease and hypertension without left ventricular 
hypertrophy. Amiodarone is the drug of choice in patients 
with advanced underlying heart disease such as history 
of heart failure, myocardial infarction, and left ventricular 
hypertrophy. The class IA antiarrhythmic agents quinidine 
and procainamide are less commonly used due to their 
side-effect profile including hypotension, anticholinergic 
action, AV node blockade, and torsade. 
- Ie 
Dronedarone is a structural analogue of amiodarone 
which is devoid of iodine atoms. It has a better 
side-effect profile with less risk of pulmonary fibrosis, 
ocular adverse effects, and skin photosensitivity. The 
ATl-IENA investigators have shown that dronaderone 
reduces the incidence of hospitalization due to 
cardiovascular events or death in patients with AF.7 
Electrical cardioversion 
Direct-current cardioversion of AF, the delivery of 
an electrical shock synchronized with the intrinsic 
actMty of the heart, was first reported by Lown 
in 1963.8 It is contraindicated in the presence of 
digitalis toxicity and hypokalaemia, and adequate 
anticoagulation prior to cardioversion is mandatory. 
Ablation of atrial fibrillation 
Achieving and maintaining sinus rhythm by 
antiarrhythmic therapy depends on their limited 
efficiency and adverse side-effects. A reproducible 
and effective treatment option of symptomatic 
patients with paroxysmal AF is catheter ablation with 
pulmonary vein isolation. Success rates of 70-90% 
have been reported.9 
Conclusion 
AF is a growing health problem which is posing 
a significant economic burden. With an ageing 
population, the number of patients with AF is 
expected to double in the next few decades. 
Effective and early treatment of hypertension and 
heart failure may reduce the occurrence of AF by 
delaying damage to the atria. The future of the 
treatment of AF is promising with the emergence 
of new antithrombotic medications, better 
antiarrhythmic agents, and improved ablation 
techniques. 
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